Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
---|---|---|---|---|---|
PMID:10746943 | IVR | 500 mg/kg/day | - | No significant effects observed | - |
IVR | 250 mg/kg/day | - | No significant effects observed | - | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decreased Dihydroxytestosterone (DHT) levels | Reproductive endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
IVR | 1500 mg/kg/day | 1500 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Decreased Dihydroxytestosterone (DHT) levels | Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
IVR | 1000 mg/kg/day | 1000 mg/kg/day | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
PMID:10966521 | IVR | 250 mg/day | - | No significant effects observed | - |
IVR | 1500 mg/day | 1500 mg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 1500 mg/day | 1500 mg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
IVR | 1500 mg/day | 1500 mg/day | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
IVR | 1500 mg/day | 1500 mg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
IVR | 500 mg/day | 500 mg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
IVR | 1000 mg/day | 1000 mg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 1000 mg/day | 1000 mg/day | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
IVR | 1000 mg/day | 1000 mg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
PMID:19344668 | IVR | 100 % | 100 % | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
IVR | 100 % | 100 % | Affects spatial memory | Neurological endocrine-mediated perturbations | |
IVR | 100 % | 100 % | Affects GABA-receptors | Neurological endocrine-mediated perturbations | |
IVR | 50 % | 50 % | Affects GABA-receptors | Neurological endocrine-mediated perturbations | |
IVR | 50 % | 50 % | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
IVR | 50 % | 50 % | Affects spatial memory | Neurological endocrine-mediated perturbations | |
PMID:19595749 | IVR | 1200 mg/kg | 1200 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
IVR | 1200 mg/kg | 1200 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.